Criterion | ACR 1982 | SLICC 2012 | EULAR/ACR 2019 | ||
Derivation | Validation | ||||
No attribution | Attribution | ||||
Specificity (%) | Specificity (%) | Specificity (%) | Specificity (%) | Specificity (%) | |
ANA | 49 | 45.2 | 19.4 | Entry criterion | |
ACLE/photosensitive rash | NR | 80.1 | 89.2 | No EULAR/ACR criterion | |
ACLE | 96 | NR | 98.8 | 98.8 | 99.0 |
Joint involvement | 37 | 43.6 | 48.4 | 86.6 | 94.6 |
Lymphopenia <1500×109/L | NR | 81.6 | 72.2 | No EULAR/ACR criterion | |
Lymphopenia <1000×109/L | NR | 94.7 | 81.4 | No EULAR/ACR criterion | |
Antiphospholipid ab. | NR | 86.0 | 88.6 | 88.6 | 86.9 |
ab, antibody; ACLE, acute cutaneous lupus erythematosus; ACR, American College of Rheumatology; ANA, antinuclear antibodies; EULAR, European League Against Rheumatism; NR, not reported; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.